Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galecto Inc.

2.99
-0.0100-0.33%
Post-market: 2.990.00000.00%16:00 EDT
Volume:16.81K
Turnover:50.56K
Market Cap:3.95M
PE:-0.16
High:3.11
Open:3.03
Low:2.93
Close:3.00
Loading ...

Company Profile

Company Name:
Galecto Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
5
Office Location:
Ole Maaloes Vej 3,Copenhagen N,Copenhagen,Capital Region of Denmark,Denmark
Zip Code:
2200
Fax:
- -
Introduction:
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Directors

Name
Position
Amit D. Munshi
Director, Chairman of the Board
Carl Goldfischer
Director
Chau Q. Khuong
Director
David Shapiro
Director
Soren Moller
Director
Stephan Christgau
Director

Shareholders

Name
Position
Hans T. Schambye
Chief Executive Officer
Anders Pedersen
Chief Operating Officer
Jonathan Freve
Chief Financial Officer
Bertil Lindmark
Chief Medical Officer